Akouos Inc (AKUS)

NASDAQ
4.64
+0.20(+4.50%)
  • Volume:
    61,113
  • Day's Range:
    4.25 - 4.73
  • 52 wk Range:
    2.32 - 13.90

AKUS Overview

Prev. Close
4.44
Day's Range
4.25-4.73
Revenue
-
Open
4.45
52 wk Range
2.32-13.9
EPS
-2.83
Volume
61,113
Market Cap
160.67M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
193,231
P/E Ratio
-
Beta
-
1-Year Change
-70.54%
Shares Outstanding
34,626,156
Next Earnings Date
Aug 18, 2022
What is your sentiment on Akouos?
or
Vote to see community's results!

Akouos Inc Company Profile

Akouos Inc Company Profile

Employees
69

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company’s precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuySell
Technical IndicatorsBuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell